脉冲生物科学 PLSE 深 沪
等待开盘 05-22 09:30:00 美东时间
25.56
-0.530
-2.03%
华盛通- 最 高26.51
- 今 开26.00
- 成交量 29.39万股
- 最 低 25.02
- 昨 收 26.09
- 总市值 17.69亿
- 52周最高 27.98
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 12.56
- 委 比 9.78%
- 总股本 6920.97万
- 历史最高 45.82
- 量 比 0.50
- 振 幅 5.71%
- 历史最低 1.18
- 每 手 1
- 风险率 3.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pulse Biosciences shares are trading higher after its Co-Chairmen purchased approximately $13.3 million worth of shares.
Pulse Biosciences shares are trading higher after its Co-Chairmen purchased app...
05-13 00:14
Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and
05-12 19:22
电话会总结 ｜ Pulse Biosciences(PLSE)2025财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Pulse Biosciences业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至2025年3月31日，现金及现金等价物为1.193亿美元，较2024年同期的3,490万美元大幅增长，较2024年年末增加120万美元。第一季度通过认股权证行权获得1,410万美元收入。 **成本费用：** GAAP总成本和费用为1,800万美元，较上年同期的1,060万美元增加740万美元。非现金股票薪酬费用为570万美元，较上年同期的180万美元大幅增加390万美元。 **净亏损：** GAAP净亏损为1,680万美元，较上年
05-05 12:26
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of $(0.25) per share from the
05-04 19:09
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Pulse Biosciences Enrolls First Patient In Its NANOPULSE-AF Study Of nPulse Cardiac Catheter System For Recurrent, Drug-Resistant, Symptomatic Paroxysmal Atrial Fibrillation
The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. "This is a
04-07 19:11
Pulse Biosciences Begins First Human Study Of New Device To Treat Small Thyroid Cancer Tumors
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
03-12 19:06
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know
The Q4 earnings report for Pulse Biosciences (NASDAQ:PLSE) was released on Thur...
02-20 05:08
Earnings Scheduled For February 19, 2026
Companies Reporting Before The Bell • Deere (NYSE:DE) is expected to report qua...
02-19 19:11
